Aberrant expression of signaling proteins in essential thrombocythemia
Dysregulated expression of signaling proteins may contribute to the pathophysiology of essential thrombocythemia (ET). This study aimed to characterize protein expression in ET and to correlate the dysregulated proteins with phenotypes and prognosis of ET patients. The expression of 128 proteins in peripheral blood neutrophils from 74 ET patients was assessed and compared with those from 29 healthy subjects and 35 polycythemia vera (PV) patients using protein pathway array. Fifteen proteins were differentially expressed between ET patients and normal controls. These dysregulated proteins were involved in the signaling pathways related with apoptosis and inflammation. Our results showed a significant overlap in protein expression between ET patients with JAK2V617F mutation and PV patients. In addition, nine proteins were associated with JAK2V617F mutation status in ET patients. Furthermore, estrogen receptor beta (ERβ) and Stat3 were independent risk factors for subsequent thrombosis during follow-up on multivariable analysis. Our study shows a broad dysregulation of signaling protein in ET patients, suggesting their roles in ET pathogenesis. The expression levels of ERβ and Stat3 could be promising predictors of subsequent thrombosis in ET patients.
KeywordsEssential thrombocythemia Signaling protein JAK2V617F mutation ERβ Stat3
We thank Dr. Li Su, Dr. Suigui Wan, Dr. Wanling Sun, Dr. Hong Zhao, and Dr. Bingxin Ji for collecting the samples and clinical information. We thank Dr. Wei Yang and Dr. Fei Yin for the technical support in PPA experiments. This study was supported in part by research funding from Xuan Wu Hospital, Capital Medical University, Beijing, China.
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, LyonGoogle Scholar
- 9.Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–1097PubMedCrossRefGoogle Scholar